- Home
- WLK vs BMRN Comparison
WLK vs BMRN Comparison
Compare WLK & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLK | BMRN |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.0B |
| IPO Year | 2004 | 1999 |
Fundamental Metrics
Financial Performance| Metric | WLK | BMRN |
|---|---|---|
| Price | $99.94 | $59.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $90.07 | $89.86 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-20-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | N/A | ★ 2.68 |
| Revenue | ★ $11,480,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | N/A | $13.53 |
| Revenue Next Year | $0.60 | $9.69 |
| P/E Ratio | ★ N/A | $22.33 |
| Revenue Growth | N/A | ★ 12.39 |
| 52 Week Low | $56.33 | $50.76 |
| 52 Week High | $118.23 | $73.51 |
Technical Indicators
Market Signals| Indicator | WLK | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 63.45 |
| Support Level | $96.68 | $57.84 |
| Resistance Level | $103.00 | $61.48 |
| Average True Range (ATR) | 4.26 | 1.69 |
| MACD | 0.89 | 0.36 |
| Stochastic Oscillator | 84.26 | 85.00 |
Price Performance
Historical ComparisonAbout WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.